{
    "nctId": "NCT06585969",
    "briefTitle": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",
    "officialTitle": "A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 504,
    "primaryOutcomeMeasure": "Primary outcome",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women aged 18 or above.\n* Radiologically/pathologically verified metastatic breast cancer.\n* ER-positive (1% or more) and HER2-low (HER2 1+ or HER2 2+/ISH-neg)10,11.\n* PAM50 Luminal B, HER2-enriched or Basal-like.\n* Performance status 0-1.\n* Evaluable disease\n\nExclusion Criteria:\n\n* Patients who are incapable of understanding the written material received\n* Patients with inaccessible tumour tissue\n* Other malignant disease within 5 years (in situ cervix and non-melanoma skin cancer excluded)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}